"10.1371_journal.pone.0062540","plos one","2013-04-29T00:00:00Z","Carlos L√≥pez-G√≥mez; Almudena Pino-√Ångeles; Teresa √ìrpez-Zafra; Mar√≠a Jes√∫s Pinto-Medel; Bego√±a Oliver-Martos; Jes√∫s Ortega-Pinazo; Carlos Arn√°iz; Cristina Guijarro-Castro; Jezabel Varad√©; Roberto √Ålvarez-Lafuente; Elena Urcelay; Francisca S√°nchez-Jim√©nez; √ìscar Fern√°ndez; Laura Leyva","Research Laboratory. Clinical Neurosciences Institute, Hospital Regional Universitario Carlos Haya, M√°laga, Spain; Department of Molecular Biology and Biochemistry, University of M√°laga, M√°laga, Spain; Department of Neurology. Clinical Neurosciences Institute, Hospital Regional Universitario Carlos Haya, M√°laga, Spain; Department of Neurology, Hospital Universitario 12 de Octubre, Madrid, Spain; Multiple Sclerosis Unit, Hospital Cl√≠nico San Carlos, IdISSC, Madrid, Spain; Centro de Investigaci√≥n Biom√©dica en Red de Enfermedades Raras (CIBERER), M√°laga, Spain; Red Espa√±ola de Esclerosis M√∫ltiple (REEM RD 07/0060), M√°laga, Spain","Conceived and designed the experiments: CLG LL. Performed the experiments: CLG APA TOZ MJPM BOM JOP. Analyzed the data: CLG APA TOZ MJPM BOM FSJ. Contributed reagents/materials/analysis tools: CA CGC JV RAL EU OF. Wrote the paper: CLG APA OF LL.","Oscar Fern√°ndez, MD, PhD has received honoraria as consultant in advisory boards, and as chairmen or lecturer in meetings, and has also participated in clinical trials and other research projects promoted by Biogen-Idec, Bayer-Schering; Merck-Serono, Teva, Novartis, Almirall and Allergan. This study was partly funded by Biogen Idec Iberia S.L. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","04","Carlos L√≥pez-G√≥mez","CL√G√",14,TRUE,2,6,6,4,TRUE,TRUE,TRUE,4,"2;3;10;13",TRUE
